Navidea Biopharmaceuticals (NAVB) Reports In-Line Q2 Loss of 7c/Share

Navidea Biopharmaceuticals (NYSE: NAVB) reported Q2 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $1.08 million.

For earnings history and earnings-related data on Navidea Biopharmaceuticals (NAVB) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• United Community Banks sells equipment finance unit for $1.9 billion
• Schwab's May activity shows margin loans nearly double